&lt;p&gt;Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study&lt;/p&gt;

Wang, Gang; Tan, Khee Giap; Ren, Hongye; Hammer-Helmich, Lene

doi:10.2147/ndt.s230403

Cited by 12 publications

(13 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It seems reasonable to assume that the observed improvement in functioning seen in patients with MDD during treatment with vortioxetine may at least in part be due to the beneficial effect of treatment on cognitive symptoms. Indeed, previous studies have shown an independent association between severity of cognitive symptoms and impairment in functioning and workplace performance in patients with MDD ( 14 – 18 ). A significant association between the severity of patient-reported cognitive symptoms (assessed using the PDQ-D-5) and health-related quality of life (assessed using the EQ-5D) has also been previously reported ( 59 ).…”

Section: Discussionmentioning

confidence: 93%

“…Cognitive symptoms are common in patients with MDD, with deficits observed across multiple domains including executive function, memory, and attention (10)(11)(12)(13). Numerous studies have shown a significant association between cognitive symptoms and functioning in MDD, which appears to be independent of the severity of mood symptoms (14)(15)(16)(17)(18).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

BackgroundRandomized controlled clinical trials have shown vortioxetine to be efficacious and well tolerated for the treatment of major depressive disorder (MDD). The Real-Life Effectiveness of Vortioxetine in Depression (RELIEVE) study was undertaken to demonstrate the effectiveness and safety of vortioxetine for the treatment of MDD in routine clinical practice.MethodsRELIEVE was a 24-week, observational, prospective cohort study in outpatients with MDD initiating treatment with vortioxetine at their physician's discretion in routine care settings in Canada, France, Italy, and the USA (NCT03555136). The primary study outcome was patient functioning assessed by the Sheehan Disability Scale (SDS). Secondary outcomes included depression severity [9-item Patient Health Questionnaire (PHQ-9)], cognitive symptoms [5-item Perceived Deficits Questionnaire-Depression (PDQ-D-5)], and cognitive performance [Digit Symbol Substitution Test (DSST)]. Mixed models of repeated measures were used to assess change from baseline at week 24, adjusted for relevant confounders.ResultsA total of 737 patients were eligible for inclusion in the full analysis set. Most patients (73.7%) reported at least one comorbid medical condition, 56.0% had comorbid anxiety and 24.4% had comorbid generalized anxiety disorder. Improvement in least-squares (LS) mean SDS score from baseline to week 24 was 8.7 points. LS mean PHQ-9, PDQ-D-5 and DSST scores improved by 7.4, 4.6, and 6.2 points, respectively. Adverse events were observed in 21.2% of patients [most commonly, nausea (8.2% of patients)].ConclusionsThese results demonstrate the effectiveness and tolerability of vortioxetine for the treatment of MDD in a large and heterogeneous patient population representative of that encountered in routine clinical practice.

show abstract

Section: Discussionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…Cognitive and functional symptoms in MDD are also inherently linked, so any improvement in cognitive and functional impairment associated with vortioxetine may be expected to improve quality of life and productivity among Chinese patients with MDD. 19 , 20 , 33 …”

Section: Discussionmentioning

confidence: 99%

“…The study planned to enroll 1000 participants, assuming that information would not be available for 40% of participants at week 8 and 38% at week 24. 20 These participant numbers were expected to result in a precision of 8% and 7% for SDS assessments at weeks 8 and 24, respectively. This also allowed for the rule of 3 to be applied for safety assessments; namely, that if an AE is not observed, there is a 95% probability of the AE occurring in <0.3% of patients.…”

Section: Methodsmentioning

confidence: 99%

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study

Wang¹,

Xiao²,

Ren³

et al. 2022

NDT

Self Cite

View full text Add to dashboard Cite

Background Major depressive disorder (MDD) affects >163 million people worldwide and is a leading cause of disability in China. Functional impairment occurs alongside cognitive symptoms, anxiety, and depression, reducing quality of life and productivity in patients with MDD. Purpose The multimodal antidepressant vortioxetine has demonstrated efficacy in relieving depressive and functional symptoms of MDD in randomized controlled trials (RCTs). The RELIEVE China study aimed to investigate the real-world effectiveness of vortioxetine in China. Patients and Methods This was an observational, prospective cohort study in patients with MDD initiating treatment with vortioxetine at physician’s discretion in China. Participants were followed up for 24 weeks and assessed at 3 time points: baseline, week 8, and week 24. The primary objective was to assess the change from baseline to weeks 8 and 24 in functional impairment as measured by Sheehan Disability Scale (SDS) total score. Additional assessments included SDS subdomains, measures of depression severity, anxiety, and cognition. The safety and tolerability of vortioxetine were also examined. Results In total, 859 patients were included in the analysis. A consistent and significant improvement in functional impairment was observed during the study, with baseline mean SDS total score (16.7 points) decreasing by 5.42 (SE, 0.22) and 8.71 (SE, 0.226) points at week 8 and week 24, respectively ( P <0.0001). Improvements in other functioning, cognitive, and anxiety assessments were also observed (all P <0.0001). A total of 74.7% of patients had responded, and 63.9% had reached remission at week 24. The tolerability profile of vortioxetine in this real-world population was consistent with the established tolerability profile for this drug. Conclusion This study demonstrated the short- and long-term effectiveness and tolerability of vortioxetine for patients with MDD in a real-world setting in China. These findings are consistent with the efficacy and safety profile observed during RCTs.

show abstract

“…Its global prevalence is estimated to be 2.4%, such a high rate that the disease should be taken seriously by people [ 4 ]. Major depression is defined by having these symptoms every day for at least 2 weeks: a depressed mood during most times of the day, and loss of interest in normal activities and relationships [ 5 ]. The global prevalence of major depression is approximately 11% [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Factors related to retinal nerve fiber layer thickness in bipolar disorder patients and major depression patients

et al. 2021

View full text Add to dashboard Cite

Background We analyzed the correlation of the clinical data with retinal nerve fiber layer (RNFL) thickness and macular thickness in bipolar disorder patients and major depression patients. The aim of this study is to explore factors that affect RNFL thickness in bipolar disorder patients and major depression patients, with a view to providing a new diagnostic strategy. Methods Eighty-two bipolar disorder patients, 35 major depression patients and 274 people who were age and gender matched with the patients were enrolled. Demographic information and metabolic profile of all participants were collected. Best-corrected visual acuity of each eye, intraocular pressure (IOP), fundus examination was performed. RNFL and macular thickness were measured by optical coherence tomography (OCT). Correlations between RNFL and macular thickness and other data were analyzed. Results RNFL and macula lutea in bipolar dipolar patients and major depression patients are thinner than normal people. Triglyceride and UA levels are the highest in the bipolar disorder group, while alanine aminotransferase (ALT) and glutamic oxalacetic transaminase (AST) levels in the depression group are the highest. Age onset and ALT are positively while uric acid (UA) is negatively correlated with RNFL thickness in bipolar dipolar patients. Cholesterol level is positively correlated with RNFL thickness while the duration of illness is correlated with RNFL thickness of left eye in major depression patients. Conclusions RNFL and macula lutea in bipolar dipolar patients and major depression patients are thinner than normal people. In bipolar disorder patients, age-onset and ALT are potential protective factors in the progress of RNFL thinning, while UA is the pathological factor.

show abstract

<p>Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study</p>

Cited by 12 publications

References 54 publications

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

Effectiveness of Vortioxetine in Patients With Major Depressive Disorder in Real-World Clinical Practice: Results of the RELIEVE Study

Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study

Factors related to retinal nerve fiber layer thickness in bipolar disorder patients and major depression patients

Contact Info

Product

Resources

About